Schwarz Pharma Presents Phase III Data on Rotigotine CDS in Early Parkinson’s Disease
Aderis Pharmaceuticals partner, Schwarz Pharma, announced that in three consecutive trials rotigotine treatment resulted in clinically relevant superiority over placebo and have shown a significant reduction in symptoms. More than 95% of those completing Phase III trials continued into an open-label extension trial.
Hopkinton, MA - Jun 23, 2004 - Aderis Pharmaceuticals partner, Schwarz Pharma, presented pivotal Phase III data on rotigotine, The Parkinson’s Patch, at the 8th International Congress of Parkinson’s Disease and Movement Disorders.
"At Aderis, we are excited about the progress of our product candidates and their potential ability to improve quality of life for millions of people. We are committed to helping patients and investors understand our progress as we achieve corporate and clinical milestones."
-Kenneth L. Rice, Jr.,
Chief Commercial Officer, Aderis Pharmaceuticals
back to top
